Rigosertib
Tortoise and the Hare: New Drug Stops Rushing Cancer Cells, Slow and Steady Healthy Cells Unharmed
ScienceDaily (Mar. 2, 2012) LINK Quote:
Clin Cancer Res. 2012 Feb 14. [Epub ahead of print] Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhem F, Eckhardt SG, Adjeii AA, Jimeno A. LINK Source Medicine, Roswell Park Cancer Institute. Abstract PURPOSE: Rigosertib (R), a dual non-ATP inhibitor of polo-like kinase and phosphatidylinositol 3-kinase pathways, and gemcitabine (G) have synergistic anti-tumor activity when combined in preclinical studies. This phase 1 study aimed to determine the recommended phase 2 dose (RPTD) of the combination of rigosertib and gemcitabine in cancer patients. Methods: Patients with solid tumors who failed standard therapy or were candidates for gemcitabine-based therapy were eligible. Gemcitabine was administered on days 1, 8 and 15 on a 28-day cycle; rigosertib on days 1, 4, 8, 11, 15 and 18. Pharmacokinetic studies were performed during an expansion cohort of advanced pancreatic ductal adenocarcinoma (PDA) patients. RESULTS: Forty patients were treated, 19 in the dose escalation phase and 21 in the expansion cohort. Dose levels evaluated were (G/R mg/m2): 750/600 (n=4), 750/1200 (3), 1000/600 (3), 1000/1200 (3) and 1000/1800 (6+21). One dose limiting toxicity (death) occurred at the highest dose level (1000/1800) tested. Non-dose limiting ≥grade 2-3 toxicities included neutropenia, lymphopenia, thrombocytopenia, fatigue, and nausea. Grade 3/4 neutropenia, thrombocytopenia and fatigue were seen in 2, 1, and 2 patients in the expansion cohort. Partial responses were observed in PDA, thymic cancer and Hodgkin's lymphoma, including gemcitabine-pretreated PDA. Rigosertib's pharmacokinetic profile was not affected by gemcitabine. CONCLUSION: The RPTD established in this study is rigosertib 1800 mg/m2 and gemcitabine 1000 mg/m2. This regimen is well tolerated with a toxicity profile of the combination similar to the profile of gemcitabine alone. Antitumor efficacy was observed in patients who previously progressed on gemcitabine-based therapy. <dl class="rprtid"><dt>PMID:</dt><dd>22338014</dd><dd> [PubMed - as supplied by publisher] </dd></dl> |
Re: Rigosertib
.................................................. ......................
|
All times are GMT -7. The time now is 09:03 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021